Astellas Pharma Inc (ALPMY) Fair Value & Analysis
Healthcare · US · Market cap $23.8B
Astellas Pharma Inc
ALPMY · US
Fair value as of: Jun 25, 2026
From 26 valuation models · updated 21 days ago
Fair value updated Jun 25, 2026, revised from $27.61 to $23.54 (−14.7%) since Jun 24, 2026. Share price −1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range $9.22 – $16.77 · fair‑value band $17.65 – $29.42 · the $13.20 price screens below the $23.54 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Astellas Pharma Inc (ALPMY) currently trades at $13.20, while our model-based Fair Value estimate is $23.54, implying the stock looks roughly 78.3% undervalued today. We read business quality at 73/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Astellas Pharma Inc generated revenue of $2.1T at a net margin of 13.6%. Revenue grew 20.7% year over year. It earns a return on equity of 17.4%. The balance sheet holds a net cash position of $35.8B. Fundamentals as of Jun 25, 2026
Our scenario range runs from $17.65 (bear case) to $29.42 (bull case); at $13.20, the current price sits below that range. The share trades about 21% below its 52-week high and 50% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -24% fair-value upside, at 78%, ALPMY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Astellas Pharma Inc reported revenue of $2.3T in FY2026 versus $1.3T in FY2022, a compound +15.0%/yr. Reported net income was $309B in FY2026, compounding +25.6%/yr from FY2022.
Is ALPMY fairly valued? → Check now
Recent news
- Nvidia CEO Huang visits Japan, unveils AI partnerships across key industries
- Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
- Pfizer Poised for Mixed Second Quarter, RBC Says
- U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin El
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc 4AB | €186.15 | €93.56 | -50% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| Novartis AG NVSN | 2,601 MXN | 2,401 MXN | -8% |
| AstraZeneca PLC ZEG | €160.70 | €128.63 | -20% |
| Novo Nordisk A/S NOVOB | kr 299.95 | kr 542.67 | +81% |
| Amgen Inc AMGN | $344.72 | $261.17 | -24% |
| Gilead Sciences, Inc GILD34 | R$314.88 | R$283.11 | -10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Astellas Pharma Inc (ALPMY) undervalued?
What is the fair value of ALPMY?
What is the quality score of ALPMY?
What is the revenue of Astellas Pharma Inc (ALPMY)?
What is the net profit margin of ALPMY?
Does Astellas Pharma Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Astellas Pharma Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.